Apyx Medical Q4 Revenue Estimate Misses Company Guidance, Loss Expected
APYX has more than doubled off its 52-week low of $0.755.
Summary
Analysts project Apyx Medical Corp. to report a loss of 6 cents per share for the fourth quarter of 2025, with an average revenue estimate of $18.4 million. This revenue projection is notably below the company's own guidance of $19.0 million to $19.2 million, issued on January 12, 2026. The discrepancy between analyst expectations and company guidance for revenue is a key point for traders, as it suggests a potential revenue miss when the company reports actual results on March 10. Investors will be watching closely to see if the company can meet its own guidance or if the lower analyst estimates are confirmed, which could impact the stock price.
At the time of this announcement, APYX was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.8M. The 52-week trading range was $0.76 to $4.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.